# Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine

> **NCT00627458** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 403 (actual)

## Conditions studied

- Acellular Pertussis
- Diphtheria
- Poliomyelitis
- Haemophilus Influenzae Type b
- Tetanus
- Hepatitis B

## Interventions

- **BIOLOGICAL:** Infanrix Hexa

## Key facts

- **NCT ID:** NCT00627458
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-01
- **Primary completion:** 2008-08-18
- **Final completion:** 2008-08-18
- **Target enrollment:** 403 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627458, "Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00627458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*